Interleukin-13: A promising therapeutic target for autoimmune disease

Yan Mei Mao, Chan Na Zhao, Jing Leng, Rui Xue Leng, Dong Qing Ye, Song Guo Zheng, Hai Feng Pan

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Interleukin-13 (IL-13) was previously thought to be a redundant presence of IL-4, but in recent years its role in immunity, inflammation, fibrosis, and allergic diseases has become increasingly prominent. IL-13 can regulate several subtypes of T helper (Th) cells and affect their transformation, including Th1, Th2, T17, etc., thus it may play an important role in immune system. Previous studies have revealed that IL-13 is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), etc. In this review, we will briefly discuss the biological features of IL-13 and summarize recent advances in the role of IL-13 in the development and pathogenesis of autoimmune diseases. This information may provide new perspectives and suggestions for the selection of therapeutic targets for autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)9-23
Number of pages15
JournalCytokine and Growth Factor Reviews
Volume45
DOIs
StatePublished - Feb 2019

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mao, Y. M., Zhao, C. N., Leng, J., Leng, R. X., Ye, D. Q., Zheng, S. G., & Pan, H. F. (2019). Interleukin-13: A promising therapeutic target for autoimmune disease. Cytokine and Growth Factor Reviews, 45, 9-23. https://doi.org/10.1016/j.cytogfr.2018.12.001